Cargando…
Calmodulin antagonists promote TRA-8 therapy of resistant pancreatic cancer
Pancreatic cancer is highly malignant with limited therapy and a poor prognosis. TRAIL-activating therapy has been promising, however, clinical trials have shown resistance and limited responses of pancreatic cancers. We investigated the effects of calmodulin(CaM) antagonists, trifluoperazine(TFP) a...
Autores principales: | Yuan, Kaiyu, Yong, Sun, Xu, Fei, Zhou, Tong, McDonald, Jay M, Chen, Yabing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694833/ https://www.ncbi.nlm.nih.gov/pubmed/26320171 |
Ejemplares similares
-
Regulation of pancreatic cancer TRAIL resistance by protein O-GlcNAcylation
por: Yang, Shan-zhong, et al.
Publicado: (2020) -
Calmodulin antagonists inhibit secretion in Paramecium
Publicado: (1983) -
Potentiation of DNA damage and cytotoxicity by calmodulin antagonists.
por: Rosenthal, S. A., et al.
Publicado: (1988) -
Trifluoperazine, a calmodulin antagonist, inhibits muscle cell fusion
Publicado: (1983) -
Dynamics and structural changes of calmodulin upon interaction with the antagonist calmidazolium
por: Léger, Corentin, et al.
Publicado: (2022)